US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
pharma · Advanced Solid Tumor · Sarcoma · PRLD
Prelude Therapeutics
Prelude Therapeutics Inc
Prelude Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
175 Innovation Boulevard, Wilmington, DE 19805, US HQ
2016 Founded
111 Employees
Public company Type
PRLD · NYSE Ticker
Company details
- Status
- Public
- HQ
- 175 Innovation Boulevard, Wilmington, DE 19805, US
- Founded
- 2016
- Employees
- 111
- Programs
- 13
- Drugs
- 5
- Patents
- 16
Prelude Therapeutics pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Prelude Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Prelude Therapeutics in public FDA and regional records.
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Prelude Therapeutics in public FDA and regional records.
-
Development asset linked to Prelude Therapeutics in public FDA and regional records.